



aTyr Pharma

aTyr Pharma to Present at Three Upcoming Conferences in November

November 3, 2016

SAN DIEGO, Nov. 3, 2016 /PRNewswire/ -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced its participation in three upcoming conferences.



aTyr Pharma senior management will provide a Physiocrine-based therapeutics overview and present the previously disclosed first clinical data for its Resolaris™ program for the treatment of facioscapulohumeral muscular dystrophy (FSHD), at the:

- FSH Society's 22nd Annual FSHD International Scientific Meeting (FSHD Connect Conference): Thursday, November 10, 2016 at the Westin Copley Place Hotel in Boston, MA

In addition, aTyr Pharma senior management will present a company overview at the following two investor conferences:

- Credit Suisse's 25th Annual Healthcare Conference: Monday, November 7, 2016 at 2:00 p.m. MT (4:00 pm ET) at the Phoenician in Scottsdale, AZ
- Piper Jaffray's 28th Annual Healthcare Conference: Tuesday, November 29, 2016 at 10:10 a.m. ET at the Lotte New York Palace in New York, NY

For the two investor conferences, the presentations will be webcast live through the "Investors" section of the aTyr Pharma website at www.atyrpharma.com. An audio replay will be available for at least 30 days following the initial presentation webcast.

About aTyr Pharma

aTyr Pharma is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological modulators. The Company's lead candidate, Resolaris™, is a potential first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component. Resolaris is currently in a Phase 1b/2 clinical trial in adult patients with facioscapulohumeral muscular dystrophy (FSHD); a Phase 1b/2 trial in adult patients with limb-girdle muscular dystrophy 2B (LGMD2B or dysferlinopathies) or FSHD; and a Phase 1b/2 trial in patients with an early onset form of FSHD. To protect this pipeline, aTyr has built an intellectual property estate comprising over 80 issued or allowed patents and over 230 pending patent applications that are owned or exclusively licensed by aTyr, including over 300 potential Physiocrine-based protein compositions. aTyr's key programs are currently focused on severe, rare diseases characterized by immune dysregulation for which there are currently limited or no treatment options. For more information, please visit <http://www.atyrpharma.com>.

Contact:

Mark Johnson

Sr. Director, Investor Relations

mjohnson@atyrpharma.com

858-223-1163

Logo - <http://photos.prnewswire.com/prnh/20120809/MM55538LOGO>

SOURCE aTyr Pharma, Inc.